ICON Central Laboratories Enhances Team with New Medical Staff AppointmentsDublin, Ireland, October 22nd 2007 – ICON plc (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointments of Dr. Joseph Schappert as Medical Director and Dr. Bodgan Podwysocki to the position of Scientific Director, Europe, at ICON Central Laboratories.
Medical Director, Dr. Schappert will be based in the ICON Central Laboratories New York facility and will oversee regulatory, quality and strategic issues worldwide and provide client support in designing appropriate laboratory testing strategies for successful protocol development. He brings over 25 years experience in infectious disease testing, cardiac markers, coagulation testing, laboratory informatics, laboratory automation and molecular diagnostics.
Prior to joining ICON, Dr. Schappert was Associate Chair, Department of Diagnostic Pathology and Laboratory Medicine, at Beth Israel Medical Center in New York City.
Dr. Bodgan Podwysocki will be based in the ICON Central Laboratories Dublin facility and serve as the Scientific Director in Europe. Dr. Podwysocki comes to ICON from Novartis Pharma, Switzerland, where he held the position of Clinical Research Scientist/Trial Leader for the Infectious Diseases, Transplantation & Immunology Global Business Unit. His extensive experience extends across clinical drug development, medical and regulatory affairs, pharmacovigilance, clinical biomarker analysis and pharmaceutical product development.
Commenting on the appointments of Dr. Schappert and Dr. Podwysocki, Robert Scott-Edwards, President of ICON Central Laboratories said, “We are delighted that two such experienced people have joined ICON. They bring with them a wealth of knowledge in laboratory medicine and drug development and we look forward to them playing a leading role in helping us to continue to enhance the service that ICON Central Laboratories provides our global customers.“
About ICON Central Laboratories
ICON Central Laboratories, a division of ICON plc, provides full service, global central laboratory services from core facilities in New York, Dublin and Singapore, as well as through a network of quality affiliate laboratories worldwide. An extensive test menu of safety, esoteric and custom-developed assays, including global flow cytometry, is complemented by dedicated, sponsor-specific project teams and a single, comprehensive database for each study as well as a user-friendly, web-based, secure remote data access system. ICON Central Laboratories offer a unique service to manage and compile laboratory data when a client’s study requires the use of local laboratories.
For more information visit www.icolabs.com
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 5500 development projects and consultancy engagements across all major therapeutic areas. ICON currently has approximately 5,400 employees, operating from 64 locations in 33 countries.
Further information is available at www.iconplc.com
Back to press releases
Medical Director, Dr. Schappert will be based in the ICON Central Laboratories New York facility and will oversee regulatory, quality and strategic issues worldwide and provide client support in designing appropriate laboratory testing strategies for successful protocol development. He brings over 25 years experience in infectious disease testing, cardiac markers, coagulation testing, laboratory informatics, laboratory automation and molecular diagnostics.
Prior to joining ICON, Dr. Schappert was Associate Chair, Department of Diagnostic Pathology and Laboratory Medicine, at Beth Israel Medical Center in New York City.
Dr. Bodgan Podwysocki will be based in the ICON Central Laboratories Dublin facility and serve as the Scientific Director in Europe. Dr. Podwysocki comes to ICON from Novartis Pharma, Switzerland, where he held the position of Clinical Research Scientist/Trial Leader for the Infectious Diseases, Transplantation & Immunology Global Business Unit. His extensive experience extends across clinical drug development, medical and regulatory affairs, pharmacovigilance, clinical biomarker analysis and pharmaceutical product development.
Commenting on the appointments of Dr. Schappert and Dr. Podwysocki, Robert Scott-Edwards, President of ICON Central Laboratories said, “We are delighted that two such experienced people have joined ICON. They bring with them a wealth of knowledge in laboratory medicine and drug development and we look forward to them playing a leading role in helping us to continue to enhance the service that ICON Central Laboratories provides our global customers.“
About ICON Central Laboratories
ICON Central Laboratories, a division of ICON plc, provides full service, global central laboratory services from core facilities in New York, Dublin and Singapore, as well as through a network of quality affiliate laboratories worldwide. An extensive test menu of safety, esoteric and custom-developed assays, including global flow cytometry, is complemented by dedicated, sponsor-specific project teams and a single, comprehensive database for each study as well as a user-friendly, web-based, secure remote data access system. ICON Central Laboratories offer a unique service to manage and compile laboratory data when a client’s study requires the use of local laboratories.
For more information visit www.icolabs.com
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specializes in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON teams have successfully conducted over 5500 development projects and consultancy engagements across all major therapeutic areas. ICON currently has approximately 5,400 employees, operating from 64 locations in 33 countries.
Further information is available at www.iconplc.com